Skip to main content
Premium Trial:

Request an Annual Quote

Pfizer and Perlegen to Study Drug Response in Major Depression Disorder

NEW YORK, Jan. 8 - Perlegen Sciences and Pfizer will jointly study drug response in patients with Major Depression Disorder, Perlegen said today.

 

Perlegen, of Mountain View, Calif., will use its genotyping technology to search for SNPs associated with drug response in clinical samples. Pfizer will provide research funding, milestone payments, and license the technology.

 

Yesterday, the two companies announced a similar collaboration in the area of metabolic syndrome.

 

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.